Arcturus Therapeutics Holdings Inc.ARCTNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank14
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P14
Within normal range
vs 5Y Ago
-0.6x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
2025-42.50%
20241.57%
202330.04%
2022-14.97%
2021200.38%
202071.96%
201998.09%
20186.68%
2017-13.45%
201636.62%